Janssen JAMJL - Search Results

1

How to Position Pasireotide LAR Treatment in Acromegaly.

Coopmans EC, Muhammad A, van der Lely AJ, Janssen JAMJL, Neggers SJCMM. Coopmans EC, et al. Among authors: janssen jamjl. J Clin Endocrinol Metab. 2019 Jun 1;104(6):1978-1988. doi: 10.1210/jc.2018-01979. J Clin Endocrinol Metab. 2019. PMID: 30608534 Review.

2

IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly.

de Herder WW, van der Lely AJ, Janssen JA, Uitterlinden P, Hofland LJ, Lamberts SW. de Herder WW, et al. Clin Endocrinol (Oxf). 1995 Oct;43(4):501-5. doi: 10.1111/j.1365-2265.1995.tb02623.x. Clin Endocrinol (Oxf). 1995. PMID: 7586626

3

Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus.

Janssen JA, Jacobs ML, Derkx FH, Weber RF, van der Lely AJ, Lamberts SW. Janssen JA, et al. J Clin Endocrinol Metab. 1997 Sep;82(9):2809-15. doi: 10.1210/jcem.82.9.4180. J Clin Endocrinol Metab. 1997. PMID: 9284701 Free article.

4

Acromegaly: the significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis.

van der Lely AJ, de Herder WW, Janssen JA, Lamberts SW. van der Lely AJ, et al. J Endocrinol. 1997 Oct;155 Suppl 1:S9-13; discussion S15-6. J Endocrinol. 1997. PMID: 9389990

5

Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy.

Janssen JA, Lamberts SW. Janssen JA, et al. Clin Endocrinol (Oxf). 2000 Jan;52(1):1-9. doi: 10.1046/j.1365-2265.2000.00922.x. Clin Endocrinol (Oxf). 2000. PMID: 10651746 Review.

6

Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.

van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW. van der Lely AJ, et al. J Clin Endocrinol Metab. 2001 Feb;86(2):478-81. doi: 10.1210/jcem.86.2.7206. J Clin Endocrinol Metab. 2001. PMID: 11157994 Free article.

7

Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance.

Muller AF, Janssen JA, Hofland LJ, Lamberts SW, Bidlingmaier M, Strasburger CJ, van der Lely AJ. Muller AF, et al. J Clin Endocrinol Metab. 2001 Feb;86(2):590-3. doi: 10.1210/jcem.86.2.7173. J Clin Endocrinol Metab. 2001. PMID: 11158013 Free article.

8

[Growth hormone receptor antagonists: potential indications].

Muller AF, Janssen JA, de Herder WW, van der Lely AJ. Muller AF, et al. Ned Tijdschr Geneeskd. 2001 Jan 13;145(2):69-73. Ned Tijdschr Geneeskd. 2001. PMID: 11225259 Review. Dutch.

9

Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.

Muller AF, Janssen JA, Lamberts SW, Bidlingmaier M, Strasburger CJ, Hofland L, van der Lely AJ. Muller AF, et al. Clin Endocrinol (Oxf). 2001 Oct;55(4):461-7. doi: 10.1046/j.1365-2265.2001.01374.x. Clin Endocrinol (Oxf). 2001. PMID: 11678828 Clinical Trial.

10

Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency.

Muller AF, Leebeek FW, Janssen JA, Lamberts SW, Hofland L, van der Lely AJ. Muller AF, et al. J Clin Endocrinol Metab. 2001 Nov;86(11):5165-71. doi: 10.1210/jcem.86.11.7987. J Clin Endocrinol Metab. 2001. PMID: 11701672 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

144 results

Search Page